Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · IEX Real-Time Price · USD
15.25
-2.18 (-12.51%)
May 18, 2022 12:48 PM EDT - Market open
Market Cap788.79M
Revenue (ttm)n/a
Net Income (ttm)-123.83M
Shares Out51.72M
EPS (ttm)-2.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume241,695
Open16.72
Previous Close17.43
Day's Range15.14 - 17.11
52-Week Range15.12 - 69.12
Betan/a
AnalystsBuy
Price Target69.62 (+356.5%)
Earnings DateMay 3, 2022

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-muta...

IndustryBiotechnology
IPO DateAug 21, 2020
Employees141
Stock ExchangeNASDAQ
Ticker SymbolKYMR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 69.62, which is an increase of 356.52% from the latest price.

Price Target
$69.62
(356.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhi...

-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting

1 week ago - GlobeNewsWire

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ: KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort ...

2 weeks ago - Benzinga

Why Kymera Therapeutics Stock Is Getting Hammered Today

The biotech upset investors today with disappointing news for its lead program.

2 weeks ago - The Motley Fool

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days,  enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring

2 weeks ago - GlobeNewsWire

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

Company to begin hosting quarterly calls to provide broad updates across pipeline Company to begin hosting quarterly calls to provide broad updates across pipeline

4 weeks ago - GlobeNewsWire

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition...

MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models ...

1 month ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

2 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and...

2 months ago - GlobeNewsWire

3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch

Is it time to buy a basket of biotech stocks?

Other symbols:ARVNPFE
3 months ago - The Motley Fool

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

3 months ago - GlobeNewsWire

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

4 months ago - GlobeNewsWire

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader...

Company plans to establish Proof-of-Mechanism and -Biology in patients in immune-inflammatory and oncology indications across its three ongoing clinical programs: IRAK4, IRAKIMiD and STAT3

4 months ago - GlobeNewsWire

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

4 months ago - GlobeNewsWire

Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says

Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.

4 months ago - Yahoo Finance

Kymera Discloses New Development Cancer Program

Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to become a best-in-class P53 stabil...

5 months ago - Benzinga

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Pla...

Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines, and favorabl...

5 months ago - GlobeNewsWire

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor...

Two presentations demonstrated Kymera's STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and so...

5 months ago - GlobeNewsWire

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Techn...

WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

5 months ago - GlobeNewsWire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

5 months ago - GlobeNewsWire

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

6 months ago - GlobeNewsWire

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SI...

WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel sma...

6 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -64.71% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474,  in Single Ascending Dose portion of Phase 1 healthy volunteer trial with  up to 96% degradation in b...

6 months ago - GlobeNewsWire